Limited effect of dopaminergic medication on straight walking and turning in early-to-moderate parkinson's disease during single and dual tasking

Frontiers in Aging Neuroscience

Volumn 8, Issue JAN, 2016, Pages

  Elshehabi, Morad ^a,b   Maier, Katrin S ^a,b   Hasmann, Sandra E ^a,b   Nussbaum, Susanne ^a,b   Herbst, Heinz ^c   Heger, Tanja ^a,b   Berg, Daniela ^a,b   Hobert, Markus A ^a,b   Maetzler, Walter ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c Neurozentrum Sophienstrasse   (Germany)

Author keywords

Dual tasking; Gait; Parkinson's disease; Turning; Wearable sensors

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

AGED; ARTICLE; ATTENTION TEST; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL-TASK PERFORMANCE (TEST); FEMALE; HUMAN; MALE; MENTAL TASK; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SINGLE-TASK PERFORMANCE (TEST); STIMULUS RESPONSE; STRAIGHT WALKING; TASK PERFORMANCE; TURNING; VELOCITY; WALKING;

EID: 84960114619     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2016.00004     Document Type: Article

References (48)

1. Almeida, Q. J., Frank, J. S., Roy, E. A., Patla, A. E., and Jog, M. S. (2007). Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease. Mov. Disord. 22, 1735-1742. doi: 10.1002/mds.21603.
2. Baker, K., Rochester, L., and Nieuwboer, A. (2008). The effect of cues on gait variability-reducing the attentional cost of walking in people with Parkinson's disease. Parkinsonism Relat. Disord. 14, 314-320. doi:10.1016/j.parkreldis.2007.09.008.
3. Baltadjieva, R., Giladi, N., Gruendlinger, L., Peretz, C., and Hausdorff, J. M. (2006). Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson's disease. Eur. J. Neurosci. 24, 1815-1820. doi:10.1111/j.1460-9568.2006.05033.x.
4. Bergareche, A., Rodríguez-Oroz, M. C., Estanga, A., Gorostidi, A., López de Munain, A., Castillo-Triviño, T., et al. (2015). DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease. Mov. Disord. doi:10.1002/mds.26478.
5. Blin, O., Ferrandez, A. M., Pailhous, J., and Serratrice, G. (1991). DOPA-sensitive and DOPA-resistant gait parameters in Parkinson's disease. J. Neurol. Sci. 103, 51-54. doi:10.1016/0022-510X(91)90283-D.
6. Bloem, B. R., Grimbergen, Y. A., Cramer, M., Willemsen, M., and Zwinderman, A. H. (2001). Prospective assessment of falls in Parkinson's disease. J. Neurol. 248, 950-958. doi:10.1007/s004150170047.
7. Bock, O. (2008). Dual-task costs while walking increase in old age for some, but not for other tasks: an experimental study of healthy young and elderly persons. J. Neuroeng. Rehabil. 5, 27. doi:10.1186/1743-0003-5-27.
8. Boonstra, T. A., van der Kooij, H., Munneke, M., and Bloem, B. R. (2008). Gait disorders and balance disturbances in Parkinson's disease: clinical update and pathophysiology. Curr. Opin. Neurol. 21, 461-471. doi:10.1097/WCO.0b013e328305bdaf.
9. Brauer, S. G., and Morris, M. E. (2010). Can people with Parkinson's disease improve dual tasking when walking? Gait Posture 31, 229-233. doi:10.1016/j.gaitpost.2009.10.011.
10. Cools, R., Barker, R. A., Sahakian, B. J., and Robbins, T. W. (2001). Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex 11, 1136-1143. doi:10.1093/cercor/11.12.1136.
11. Cools, R., Barker, R. A., Sahakian, B. J., and Robbins, T. W. (2003). L-DOPA medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 41, 1431-1441. doi:10.1016/S0028-3932(03)00117-9.
12. Curtze, C., Nutt, J. G., Carlson-Kuhta, P., Mancini, M., and Horak, F. B. (2015). Levodopa is a double-edged sword for balance and gait in people with Parkinson's disease. Mov. Disord. 30, 1361-1370. doi:10.1002/mds.26269.
13. Dubois, B., and Pillon, B. (1996). Cognitive deficits in Parkinson's disease. J. Neurol. 244, 2-8. doi:10.1007/PL00007725.
14. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198. doi:10.1016/0022-3956(75)90026-6.
15. Galna, B., Lord, S., Burn, D. J., and Rochester, L. (2015). Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. Mov. Disord. 30, 359-367. doi:10.1002/mds.26110.
16. Galna, B., Lord, S., and Rochester, L. (2013). Is gait variability reliable in older adults and Parkinson's disease? Towards an optimal testing protocol. Gait Posture 37, 580-585. doi:10.1016/j.gaitpost.2012.09.025.
17. Gibb, W. R., and Lees, A. J. (1988). A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 38, 1402-1406. doi:10.1212/WNL.38.9.1402.
18. Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., et al. (2008). Movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129-2170. doi:10.1002/mds.22340.
19. Hackney, M. E., and Earhart, G. M. (2010). The effects of a secondary task on forward and backward walking in Parkinson's disease. Neurorehabil. Neural Repair 24, 97-106. doi:10.1177/1545968309341061.
20. Hass, C. J., Malczak, P., Nocera, J., Stegemöller, E. L., Shukala, A., Malaty, I., et al. (2012). Quantitative normative gait data in a large cohort of ambulatory persons with Parkinson's disease. PLoS ONE 7:e42337. doi:10.1371/journal.pone.0042337.
21. Hausdorff, J. M., Balash, J., and Giladi, N. (2003). Effects of cognitive challenge on gait variability in patients with Parkinson's disease. J. Geriatr. Psychiatry Neurol. 16, 53-58. doi:10.1177/0891988702250580.
22. Hobert, M. A., Niebler, R., Meyer, S. I., Brockmann, K., Becker, C., Huber, H., et al. (2011). Poor trail making test performance is directly associated with altered dual task prioritization in the elderly-baseline results from the TREND study. PLoS ONE 6:e27831. doi:10.1371/journal.pone.0027831.
23. Hoehn, M. M., and Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. Neurology 17, 427-442. doi:10.1212/WNL.17.5.427.
24. Hong, M., and Earhart, G. M. (2010). Effects of medication on turning deficits in individuals with Parkinson's disease. J. Neurol. Phys. Ther. 34, 11-16. doi:10.1097/NPT.0b013e3181d070fe.
25. Lees, A. J., Hardy, J., and Revesz, T. (2009). Parkinson's disease. Lancet 373, 2055-2066. doi:10.1016/S0140-6736(09)60492-X.
26. Lord, S., Baker, K., Nieuwboer, A., Burn, D., and Rochester, L. (2011). Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction? J. Neurol. 258, 566-572. doi:10.1007/s00415-010-5789-8.
27. Lord, S., Galna, B., Verghese, J., Coleman, S., Burn, D., and Rochester, L. (2013). Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J. Gerontol. A Biol. Sci. Med. Sci. 68, 820-827. doi:10.1093/gerona/gls255.
28. Maetzler, W., Nieuwhof, F., Hasmann, S. E., and Bloem, B. R. (2013). Emerging therapies for gait disability and balance impairment: promises and pitfalls. Mov. Disord. 28, 1576-1586. doi:10.1002/mds.25682.
29. Mancini, M. (2011). Mobility lab to assess balance and gait with synchronized body-worn sensors. J. Bioeng. Biomed. Sci. (Suppl. 1), 007. doi:10.4172/2155-9538.S1-007.
30. McNeely, M. E., Duncan, R. P., and Earhart, G. M. (2012). Medication improves balance and complex gait performance in Parkinson disease. Gait Posture 36, 144-148. doi:10.1016/j.gaitpost.2012.02.009.
31. McNeely, M. E., and Earhart, G. M. (2011). The effects of medication on turning in people with Parkinson disease with and without freezing of gait. J. Parkinsons Dis. 1, 259-270. doi:10.3233/JPD-2011-11030.
32. Mirelman, A., Gurevich, T., Giladi, N., Bar-Shira, A., Orr-Urtreger, A., and Hausdorff, J. M. (2011). Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann. Neurol. 69, 193-197. doi:10.1002/ana.22165.
33. Muslimovic, D., Post, B., Speelman, J. D., and Schmand, B. (2005). Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239-1245. doi:10.1212/01.wnl.0000180516.69442.95.
34. O'Shea, S., Morris, M. E., and Iansek, R. (2002). Dual task interference during gait in people with Parkinson disease: effects of motor versus cognitive secondary tasks. Phys. Ther. 82, 888-897.
35. O'Sullivan, J. D., Said, C. M., Dillon, L. C., Hoffman, M., and Hughes, A. J. (1998). Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov. Disord. 13, 900-906. doi:10.1002/mds.870130607.
36. Plotnik, M., Giladi, N., and Hausdorff, J. M. (2007). A new measure for quantifying the bilateral coordination of human gait: effects of aging and Parkinson's disease. Exp. Brain Res. 181, 561-570. doi:10.1007/s00221-007-0955-7.
37. Rochester, L., Baker, K., Nieuwboer, A., and David, B. (2011). Targeting DOPA-sensitive and DOPA-resistant gait dysfunction in Parkinson's disease: selective responses to internal and external cues. Mov. Disord. 26, 430-435. doi:10.1002/mds.23450.
38. Rochester, L., Yarnall, A. J., Baker, M. R., David, R. V., Lord, S., Galna, B., et al. (2012). Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 135(Pt 9), 2779-2788. doi:10.1093/brain/aws207.
39. Salarian, A., Zampieri, C., Horak, F. B., Carlson-Kuhta, P., Nutt, J. G., and Aminian, K. (2009). Analyzing 180° turns using an inertial system reveals early signs of progression of Parkinson's disease. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2009, 224-227. doi:10.1109/IEMBS.2009.5333970.
40. Schaafsma, J. D., Giladi, N., Balash, Y., Bartels, A. L., Gurevich, T., and Hausdorff, J. M. (2003). Gait dynamics in Parkinson's disease: relationship to parkinsonian features, falls and response to levodopa. J. Neurol. Sci. 212, 47-53. doi:10.1016/S0022-510X(03)00104-7.
41. Schrag, A., Sampaio, C., Counsell, N., and Poewe, W. (2006). Minimal clinically important change on the Unified Parkinson's Disease Rating Scale. Mov. Disord. 21, 1200-1207. doi:10.1002/mds.20914.
42. Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., and Weiner, W. J. (2010). The clinically important difference on the Unified Parkinson's Disease Rating Scale. Arch. Neurol. 67, 64-70. doi:10.1001/archneurol.2009.295.
43. Silsupadol, P., Siu, K. C., Shumway-Cook, A., and Woollacott, M. H. (2006). Training of balance under single-and dual-task conditions in older adults with balance impairment. Phys. Ther. 86, 269-281. doi:10.1016/S0966-6362(05)80442-4.
44. Smulders, K., van Nimwegen, M., Munneke, M., Bloem, B. R., Kessels, R. P., and Esselink, R. A. (2013). Involvement of specific executive functions in mobility in Parkinson's disease. Parkinsonism Relat. Disord. 19, 126-128. doi:10.1016/j.parkreldis.2012.06.010.
45. Song, J., Sigward, S., Fisher, B., and Salem, G. J. (2012). Altered dynamic postural control during step turning in persons with early-stage Parkinson's disease. Parkinsons Dis. 2012:386962. doi:10.1155/2012/386962.
46. Stack, E., Jupp, K., and Ashburn, A. (2004). Developing methods to evaluate how people with Parkinson's disease turn 180 degrees: an activity frequently associated with falls. Disabil. Rehabil. 26, 478-484. doi:10.1080/09638280410001663085.
47. Vingerhoets, F. J., Schulzer, M., Calne, D. B., and Snow, B. J. (1997). Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann. Neurol. 41, 58-64. doi:10.1002/ana.410410111.
48. Yogev-Seligmann, G., Hausdorff, J. M., and Giladi, N. (2008). The role of executive function and attention in gait. Mov. Disord. 23, 329-342. doi:10.1002/mds.21720.